U.K. Cost Watchdog Rejects Lucentis’ Extended Use In Eye Disease
This article was originally published in The Pink Sheet Daily
NICE’s draft rejection of Lucentis for use in secondary ophthalmologic indications comes as competition looms from Eylea in key AMD setting
You may also be interested in...
The Atlanta-based ophthalmology company hopes to succeed in third try with FDA, but must split its focus with Europe as it tries to roll out launches in several countries at once.
Britain's cost watchdog NICE changed its mind on Lucentis, and now recommends it for treating diabetic macular edema, after Novartis offered a steeper discount – but the eye drug’s price tag remains high, so only a subgroup of British patients will receive it.
Regeneron has designed the launch strategy of its bimonthly wet AMD injection Eylea to head off any reimbursement issues.